Clinical Application of Oncolytic Viruses: A Systematic Review

Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab

(2020) Ciara M. Kelly et al.   JAMA Oncology

Viral targeting of non-muscle invasive bladder cancer and priming of anti-tumour immunity following intravesical Coxsackievirus A21

(2019) Nicola E Annels et al.   CLINICAL CANCER RESEARCH

Achieving systemic delivery of oncolytic viruses

(2019) Claudia Hill et al.   Expert Opinion on Drug Delivery

A Randomized Double-Blind Phase II Study of the Seneca Valley Virus (NTX-010) versus Placebo for Patients with Extensive-Stage SCLC (ES SCLC) Who Were Stable or Responding after at Least Four Cycles of Platinum-Based Chemotherapy: North Central Cancer Treatment Group (Alliance) N0923 Study

(2019) Erin L. Schenk et al.   Journal of Thoracic Oncology

A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer

(2018) Yoshiki Hirooka et al.   BMC CANCER

Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma

(2018) Jason Chesney et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB–IVM1c melanoma

(2018) Jason Chesney et al.   MELANOMA RESEARCH

Recurrent Glioblastoma Treated with Recombinant Poliovirus

(2018) Annick Desjardins et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy

(2018) Marie-Claude Bourgeois-Daigneault et al.   Science Translational Medicine

Talimogene laherparepvec: First in class oncolytic virotherapy

(2018) Robert M. Conry et al.   Human Vaccines & Immunotherapeutics

A Phase II Study of Pelareorep (REOLYSIN®) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma

(2018) Devalingam Mahalingam et al.   Cancers

LBA40Phase Ib KEYNOTE-200: A study of an intravenously delivered oncolytic virus, coxsackievirus A21 in combination with pembrolizumab in advanced NSCLC and bladder cancer patients

(2018) C M Rudin et al.   ANNALS OF ONCOLOGY

Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy

(2018) Carmela Passaro et al.   CLINICAL CANCER RESEARCH

Seneca Valley Virus Exploits TEM8, a Collagen Receptor Implicated in Tumor Growth

(2018) David J. Evans et al.   Frontiers in Oncology

Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study

(2017) David E. Cohn et al.   GYNECOLOGIC ONCOLOGY

Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma

(2017) A Dispenzieri et al.   LEUKEMIA

Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial

(2017) Karsten Geletneky et al.   MOLECULAR THERAPY

Oncolytic Virotherapy: A Contest between Apples and Oranges

(2017) Stephen J. Russell et al.   MOLECULAR THERAPY

An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non–muscle-invasive bladder cancer: Interim results

(2017) Vignesh T. Packiam et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy

(2017) Zuqiang Liu et al.   Nature Communications

Coxsackievirus A21 Synergizes with Checkpoint Inhibitors

(2017)   Cancer Discovery

Oncolytic Adenoviruses Armed with Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy

(2017) Riikka Havunen et al.   Molecular Therapy-Oncolytics

Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection

(2017) Rocio Garcia-Carbonero et al.   Journal for ImmunoTherapy of Cancer

Vectorized Gene Therapy of Liver Tumors: Proof of Concept of TG4023 (MVA-FCU1) in Combination with Flucytosine

(2016) F. Husseini et al.   ANNALS OF ONCOLOGY

Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy

(2016) E Ilett et al.   GENE THERAPY

Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma

(2016) Robert H. I. Andtbacka et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges

(2016) Chrisann Kyi et al.   Immunotherapy

Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma

(2016) Igor Puzanov et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase 1 Study of Intravenous Oncolytic Poxvirus (vvDD) in Patients With Advanced Solid Cancers

(2016) Stephanie Downs-Canner et al.   MOLECULAR THERAPY

Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma

(2016) Anne M Noonan et al.   MOLECULAR THERAPY

Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma

(2016) Lee A. Wheeler et al.   NEURO-ONCOLOGY

Noninvasive Assessment of Losartan-Induced Increase in Functional Microvasculature and Drug Delivery in Pancreatic Ductal Adenocarcinoma

(2016) Vidhya Kumar et al.   Translational Oncology

Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition

(2016) Patricia Kleinpeter et al.   OncoImmunology

Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy

(2015) F. J. Kohlhapp et al.   CLINICAL CANCER RESEARCH

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

(2015) Robert H.I. Andtbacka et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer

(2015) Se Hoon Park et al.   MOLECULAR THERAPY

Complement Inhibition Prevents Oncolytic Vaccinia Virus Neutralization in Immune Humans and Cynomolgus Macaques

(2015) Laura Evgin et al.   MOLECULAR THERAPY

Phase 1 Study of Intratumoral Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus, in Pediatric Cancer Patients

(2015) Timothy P Cripe et al.   MOLECULAR THERAPY

First-in-man Study of Western Reserve Strain Oncolytic Vaccinia Virus: Safety, Systemic Spread, and Antitumor Activity

(2015) Herbert J Zeh et al.   MOLECULAR THERAPY

A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: A Children's Oncology Group Phase I Consortium report

(2015) E . Anders Kolb et al.   PEDIATRIC BLOOD & CANCER

Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors

(2015) Karishma Rajani et al.   Viruses-Basel

Immunological data from cancer patients treated with Ad5/3 E2F Δ24 GMCSF suggests utility for tumor immunotherapy

(2015) Otto Hemminki et al.   Oncotarget

A Phase I Trial of Single-Agent Reolysin in Patients with Relapsed Multiple Myeloma

(2014) D. W. Sborov et al.   CLINICAL CANCER RESEARCH

Phase I Trial of Cyclophosphamide as an Immune Modulator for Optimizing Oncolytic Reovirus Delivery to Solid Tumors

(2014) V. Roulstone et al.   CLINICAL CANCER RESEARCH

Results of a Randomized Phase I Gene Therapy Clinical Trial of Nononcolytic Fowlpox Viruses Encoding T Cell Costimulatory Molecules

(2014) Howard L. Kaufman et al.   HUMAN GENE THERAPY

Prospective Randomized Phase 2 Trial of Intensity Modulated Radiation Therapy With or Without Oncolytic Adenovirus-Mediated Cytotoxic Gene Therapy in Intermediate-Risk Prostate Cancer

(2014) Svend O. Freytag et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Reovirus Activates Human Dendritic Cells to Promote Innate Antitumor Immunity

(2014) Fiona Errington et al.   JOURNAL OF IMMUNOLOGY

Remission of Disseminated Cancer After Systemic Oncolytic Virotherapy

(2014) Stephen J. Russell et al.   MAYO CLINIC PROCEEDINGS

Phase 1 Clinical Trial of Intratumoral Reovirus Infusion for the Treatment of Recurrent Malignant Gliomas in Adults

(2014) Kimberly P Kicielinski et al.   MOLECULAR THERAPY

A Phase 1 Trial of Oncolytic HSV-1, G207, Given in Combination With Radiation for Recurrent GBM Demonstrates Safety and Radiographic Responses

(2014) James M Markert et al.   MOLECULAR THERAPY

Phase I trial of Seneca Valley Virus (NTX-010) in children with relapsed/refractory solid tumors: A report of the Children's Oncology Group

(2014) Michael J. Burke et al.   PEDIATRIC BLOOD & CANCER

Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy

(2014) D. Zamarin et al.   Science Translational Medicine

Reporter gene imaging identifies intratumoral infection voids as a critical barrier to systemic oncolytic virus efficacy

(2014) Amber Miller et al.   Molecular Therapy-Oncolytics

Intraprostatic distribution and long-term follow-up after AdV-tk immunotherapy as neoadjuvant to surgery in patients with prostate cancer

(2013) A Rojas-Martínez et al.   CANCER GENE THERAPY

Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy

(2013) Y. Huang et al.   CANCER RESEARCH

Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans

(2013) C. J. Breitbach et al.   CANCER RESEARCH

Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF-Coding Oncolytic Adenovirus

(2013) A. Kanerva et al.   CLINICAL CANCER RESEARCH

A phase I clinical trial of Ad5/3-Δ24, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer

(2013) Kenneth H. Kim et al.   GYNECOLOGIC ONCOLOGY

Granulocyte-Macrophage Colony-Stimulating Factor-Armed Oncolytic Measles Virus Is an Effective Therapeutic Cancer Vaccine

(2013) Christian Grossardt et al.   HUMAN GENE THERAPY

At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy

(2013) Andrew M. Intlekofer et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer

(2013) Jeong Heo et al.   NATURE MEDICINE

Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies

(2012) E. M. Karapanagiotou et al.   CLINICAL CANCER RESEARCH

REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors

(2012) Don G. Morris et al.   INVESTIGATIONAL NEW DRUGS

A First in Human Phase 1 Study of CG0070, a GM-CSF Expressing Oncolytic Adenovirus, for the Treatment of Nonmuscle Invasive Bladder Cancer

(2012) James M. Burke et al.   JOURNAL OF UROLOGY

Phase II Trial of Intravenous Administration of Reolysin® (Reovirus Serotype-3-dearing Strain) in Patients with Metastatic Melanoma

(2012) Evanthia Galanis et al.   MOLECULAR THERAPY

Phase I Clinical Study of Seneca Valley Virus (SVV-001),a Replication-Competent Picornavirus, in Advanced Solid Tumors with Neuroendocrine Features

(2011) C. M. Rudin et al.   CLINICAL CANCER RESEARCH

Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors

(2011) Sari Pesonen et al.   INTERNATIONAL JOURNAL OF CANCER

Targeting Tumor Vasculature With an Oncolytic Virus

(2011) Caroline J Breitbach et al.   MOLECULAR THERAPY

Immunological Effects of Low-dose Cyclophosphamide in Cancer Patients Treated With Oncolytic Adenovirus

(2011) Vincenzo Cerullo et al.   MOLECULAR THERAPY

A Mechanistic Proof-of-concept Clinical Trial With JX-594, a Targeted Multi-mechanistic Oncolytic Poxvirus, in Patients With Metastatic Melanoma

(2011) Tae-Ho Hwang et al.   MOLECULAR THERAPY

Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans

(2011) Caroline J. Breitbach et al.   NATURE

A phase I study of KH901, a conditionally replicating granulocyte-macrophage colony-stimulating factor: Armed oncolytic adenovirus for the treatment of head and neck cancers

(2010) Jianhua Chang et al.   CANCER BIOLOGY & THERAPY

A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancreatic cancer

(2010) A Nakao et al.   CANCER GENE THERAPY

Phase I Trial of Intraperitoneal Administration of an Oncolytic Measles Virus Strain Engineered to Express Carcinoembryonic Antigen for Recurrent Ovarian Cancer

(2010) E. Galanis et al.   CANCER RESEARCH

Two-Stage Phase I Dose-Escalation Study of Intratumoral Reovirus Type 3 Dearing and Palliative Radiotherapy in Patients with Advanced Cancers

(2010) K. J. Harrington et al.   CLINICAL CANCER RESEARCH

A Phase I Study of the Combination of Intravenous Reovirus Type 3 Dearing and Gemcitabine in Patients with Advanced Cancer

(2010) M. P. Lolkema et al.   CLINICAL CANCER RESEARCH

A Phase I Study of a Tropism-Modified Conditionally Replicative Adenovirus for Recurrent Malignant Gynecologic Diseases

(2010) K. J. Kimball et al.   CLINICAL CANCER RESEARCH

Phase I/II Study of Oncolytic HSVGM-CSF in Combination with Radiotherapy and Cisplatin in Untreated Stage III/IV Squamous Cell Cancer of the Head and Neck

(2010) K. J. Harrington et al.   CLINICAL CANCER RESEARCH

REO-10: A Phase I Study of Intravenous Reovirus and Docetaxel in Patients with Advanced Cancer

(2010) C. Comins et al.   CLINICAL CANCER RESEARCH

Oncolytic Adenovirus ICOVIR-7 in Patients with Advanced and Refractory Solid Tumors

(2010) P. Nokisalmi et al.   CLINICAL CANCER RESEARCH

Phase I/II Study of Oncolytic Herpes Simplex Virus NV1020 in Patients with Extensively Pretreated Refractory Colorectal Cancer Metastatic to the Liver

(2010) Sunil K. Geevarghese et al.   HUMAN GENE THERAPY

Adaptive Antiviral Immunity Is a Determinant of the Therapeutic Success of Oncolytic Virotherapy

(2010) Paul T Sobol et al.   MOLECULAR THERAPY

Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma

(2009) Neil N. Senzer et al.   JOURNAL OF CLINICAL ONCOLOGY

A Phase I Study of Telomerase-specific Replication Competent Oncolytic Adenovirus (Telomelysin) for Various Solid Tumors

(2009) John Nemunaitis et al.   MOLECULAR THERAPY

A Phase I Study of Intravenous Oncolytic Reovirus Type 3 Dearing in Patients with Advanced Cancer

(2008) L. Vidal et al.   CLINICAL CANCER RESEARCH

Tumor Infection by Oncolytic Reovirus Primes Adaptive Antitumor Immunity

(2008) R. J. Prestwich et al.   CLINICAL CANCER RESEARCH

A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients

(2008) J-L Li et al.   GENE THERAPY

Potential for efficacy of the oncolytic Herpes simplex virus 1716 in patients with oral squamous cell carcinoma

(2008) Alastair T. M. Mace et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial

(2008) Byeong-Ho Park et al.   LANCET ONCOLOGY

A Phase I Trial of Intratumoral Administration of Reovirus in Patients With Histologically Confirmed Recurrent Malignant Gliomas

(2008) Peter Forsyth et al.   MOLECULAR THERAPY

A Herpes Oncolytic Virus Can Be Delivered Via the Vasculature to Produce Biologic Changes in Human Colorectal Cancer

(2008) Yuman Fong et al.   MOLECULAR THERAPY

Oncolytic herpes virus with defective ICP6 specifically replicates in quiescent cells with homozygous genetic mutations in p16

(2008) M Aghi et al.   ONCOGENE